In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.
On March 15, 2018, Interros Group acquired a 2.1% stake in Norilsk Nickel from Crispian Investments Limited – a subsidiary company of the Millhouse Group. To date, the Interros Group holds 32.9% shares in OJSC MMC Norilsk Nickel.
The JV aims at becoming one of the world’s largest producers of platinum group metals with a target annual production volume of approximately 70-100 tons of PGMs.